Navigation Links
Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
Date:2/5/2008

so developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements contained in this press release, the upcoming webcast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and SHENZHEN, China , July ... today the purchase of an Irys™System by ... selected BioNano,s platform to enable comprehensive exploration of human ... for various organisms of interest, including those where no ... together to develop new methods for multiplexing on the ...
(Date:7/31/2014)... Although RNA-Sequencing is a relatively ... analyses appearing around 2008, RNA-Sequencing has rapidly evolved ... In the last several years, assays have improved ... smaller input amounts, process degraded RNA, and perform ... the bioinformatics side, there have been improvements in ...
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a CNN ... Cancer News. , Bill Bro, KCA CEO, says, “We’re ... an international news organization. When we began using iReport last ... month’s program highlights news of an enzyme that is lost ... study. Kidney Cancer News also presents a report on outcomes ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
Breaking Biology Technology:BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... 1, 2011 Life Technologies Corporation (Nasdaq: ... webcasting management presentations to investors as part of the ... which is being held at the company,s headquarters in ...  Mark Stevenson, Life Technologies, President and Chief Operating Officer, ...
... NEW YORK, March 1, 2011 NeoStem, Inc. (NYSE Amex: ... in the U.S. and China, announced today that Dr. Robert ... Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc., has been ... 6th Annual New York Stem Cell Summit. The Summit will ...
... BioNeutral Group, Inc. (OTC Bulletin Board: ... announced that its wholly-owned subsidiary, BioNeutral Services, Inc., has ... (KEDFA) to receive up to $280,000 in development incentives ... February 24 meeting, six companies, including BioNeutral Services, Inc., ...
Cached Biology Technology:Life Technologies to Webcast Investor Presentation as Part of the UBS West Coast Life Sciences & Diagnostics Bus Trip 2Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 2Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 3Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 4BioNeutral Group to Receive Economic Development Incentives 2BioNeutral Group to Receive Economic Development Incentives 3
(Date:7/31/2014)... marine noise can affect animal movement and communication, with ... and Exeter and the cole Pratique des Hautes tudes ... stops embryonic development and increases larval mortality in sea ... Stylocheilus striatus used in this study) usually hatch ... on toxic alga but this study, conducted in a ...
(Date:7/30/2014)... at New York University is paving the way ... in civilians and military troops exposed to poisonous ... , An article in the current issue of ... in detoxifying organophosphates, which are compounds commonly used ... was developed by NYU School of Engineering Associate ...
(Date:7/30/2014)... in Lewis Carroll,s Through the Looking Glass, collaborators ... of Singapore improved a 35-year-old ecology model to ... millions of years. , The new model, called ... "Red Queen Effect," an evolutionary hypothesis introduced by ... that organisms must constantly increase their fitness (or ...
Breaking Biology News(10 mins):Boat noise impacts development and survival of sea hares 2Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... likely impact of ocean acidification on shellfish and other marine ... is published this week (date) in the journal Global ... because some of the increased carbon dioxide humans are adding ... water to produce an acid. The results suggest that ...
... by the National Science Foundation (NSF) found state agency ... fiscal year 2009, a 7 percent increase over the ... details nationwide and state-by-state totals of R&D activities performed ... first time survey data are available by individual state ...
... release is available in German . Tomato ... with a genetic defect that made the fruits mature very slowly, ... were delighted as it gave them more time to transport the ... it would be sold. At the stores, the tomatoes could then ...
Cached Biology News:New study helps predict impact of ocean acidification on shellfish 2New study helps predict impact of ocean acidification on shellfish 3Ethylene of no effect -- why peppers do not mature after picking 2
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... all plate washing needs in both the 384-well ... 384 provides an excellent solution for a variety ... development, Screening or Lead Optimization) and Research. ... 384 has set a standard for ultra-fast washing ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
Biology Products: